Bartter's and Gitelman's syndrome

Area of Science:

• Nephrology
• Genetics
• Molecular Biology

Background:

• Bartter's syndrome and Gitelman's syndrome are heterogeneous hypokalemic salt-losing tubulopathies with distinct pathophysiologies.
• Understanding these differences is key for accurate diagnosis and management.
• Recent advancements have identified new variants and associated clinical features.

Purpose of the Study:

• To review the clinical presentations of Bartter's syndrome and Gitelman's syndrome.
• To evaluate the applicability of a physiologic classification system for salt-losing tubulopathies.
• To highlight the importance of pharmacologic characterization for patient management.

Main Methods:

• Review of clinical presentations of Bartter's syndrome and Gitelman's syndrome.
• Classification of salt-losing tubulopathies based on physiologic defects in the thick ascending limb of Henle's loop and distal convoluted tubule (DCT).
• Pharmacologic testing (pharmacotyping) to assign specific Bartter's syndrome variants to physiologic groups.

Main Results:

• Salt-losing tubulopathies are classified into loop disorders, DCT disorders, and combined loop/DCT disorders.
• Bartter's syndrome V is categorized as a DCT disorder, while transient antenatal Bartter's syndrome fits the combined loop/DCT category.
• Loop disorders present with diverse clinical features including polyhydramnios, hyperprostaglandinuria, nephrogenic diabetes insipidus, nephrocalcinosis, and neonatal hyperparathyroidism.

Conclusions:

• A physiologic classification, supported by pharmacotyping, is essential for diagnosing and managing Bartter's syndrome and Gitelman's syndrome.
• Accurate characterization guides therapeutic strategies in the absence of gene therapy.
• Recognizing the spectrum of clinical presentations and associated features improves patient care.